In addition, TG2 expression was assessed in CAFs from other types of tumors; in hepatocellular carcinoma, it was associated with a CAF-driven EMT via the IL-6/IL-6R/STAT3 axis [140], while in pancreatic cancer, it correlates with a worse prognosis since the TG2 secreted by cancer cells supports matrix deposition and promotes neoplastic cell proliferation via the activation of the YAP/TAZ signaling pathway [59]. This evidence concerns the gene TGM2 and pancreatic neoplasm.